HLB liver cancer drug enters FDA review, decision expected by April

Korea Times News ·
Health Medicine South Korea

Korean biopharmaceutical group HLB is getting a second shot at U.S. Food and Drug Administration (FDA) approval for its flagship liver cancer therapy. The FDA has officially accepted a resubmitted application from HLB’s California-based drug development arm, Elevar Therapeutics, to evaluate a combination treatment for advanced liver cancer, setting a target decision date of April 9. Elevar said…

Read original article on Korea Times News →

Related news